Q4 2025 · 13F-HR
CAXTON CORPholdings as filed
Filed 2026-02-13 · accession 0000919574-26-000956
$4.3M
Reported value
11
Positions
2025-12-31
Period end
The Brief · CAXTON CORP · Q4 2025
AI · grounded in 13F
CAXTON CORP closed its position in RZLT, reducing its exposure by $18.68M. The fund established new positions in SYRE for $292,194 and XFOR for $62,227. Additionally, the fund increased its holdings in IKT by 73.57% and BRK/B by 9.06%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78463V107 | GLD | SPDR GOLD TR | $2.8M | 64.5% | 6,964 | Common | SOLE |
| 084670702 | BRK/B | BERKSHIRE HATHAWAY INC DEL | $356,771 | 8.34% | 710 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $292,194 | 6.83% | 8,919 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $210,058 | 4.91% | 15,688 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $176,468 | 4.12% | 18,773 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $158,386 | 3.70% | 29,495 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $138,453 | 3.24% | 13,943 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $62,227 | 1.45% | 15,557 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $58,328 | 1.36% | 28,453 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $39,371 | 0.92% | 10,527 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $27,053 | 0.63% | 18,403 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.